Beyond Air, Inc. (XAIR)
Stock Price:
$5.44 USD
-0.17 (-3.03%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $5.43 -0.01 (-0.18%) Oct 27, 5:02 PM
Key Info
| Market Cap |
93.28M |
| Revenue (ttm) |
991,796 |
| Net Income (ttm) |
-20.50M |
| Shares Out |
17.15M |
| EPS (ttm) |
-1.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$5.44 |
| Previous Close |
$5.61 |
| Change ($) |
-0.17 |
| Change (%) |
-3.03% |
| Day's Open |
5.57 |
| Day's Range |
5.40 - 5.57 |
| Day's Volume |
49,152 |
| 52-Week Range |
3.45 - 12.50 |
More Stats
| Market Cap |
93.28M |
| Enterprise Value |
73.82M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
17.15M |
| Float |
14.19M |
| EPS (basic) |
-1.53 |
| EPS (diluted) |
-1.53 |
| FCF / Share |
-1.10 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.54M |
| Short Ratio |
12.25 |
| Short % of Float |
10.85% |
| Beta |
-0.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
94.05 |
| PB Ratio |
5.58 |
| Revenue |
991,796 |
| Operating Income |
-20.86M |
| Net Income |
-20.50M |
| Free Cash Flow |
-18.11M |
| Net Cash |
19.46M |
| Net Cash / Share |
1.13 |
| Gross Margin |
140.16% |
| Operating Margin |
-2,103.26% |
| Profit Margin |
-2,120.00% |
| FCF Margin |
-1,825.94% |
| ROA |
-65.20% |
| ROE |
-157.11% |
| ROIC |
-473.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.25*
(143.57% upside)
Low
9.00
Current: $5.44
High
17.00
Target: 13.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 1.39 | 7.72 | - | - |
| Revenue Growth | -82% | - | - | - |
| Gross Profit | 1.39 | 7.72 | - | - |
| Operating Income | -18.14 | -3.06 | -11.07 | -2.33 |
| Net Income | 20.99 | -6.56 | -18.04 | 3.72 |
| Shares Outstanding | 11.51 | 8.50 | 6.00 | 1.45 |
| Earnings Per Share | -1.78 | -0.77 | -3.01 | -2.69 |
| Operating Cash Flow | -15.25 | 1.34 | -7.12 | -0.69 |
| Capital Expenditures | -0.04 | -0.06 | -0.24 | 0.01 |
| Free Cash Flow | -15.29 | 1.28 | -7.36 | -0.68 |
| Cash & Equivalents | 25.47 | 7.90 | 1.81 | 0.01 |
| Total Debt | 4.88 | 0.26 | 0.03 | 3.31 |
| Net Cash / Debt | 20.59 | 7.64 | 1.78 | -3.31 |
| Assets | 27.43 | 9.43 | 2.19 | 0.24 |
| Liabilities | 9.34 | 5.40 | 10.57 | 4.93 |
| Book Value | 18.09 | 4.02 | -8.38 | -4.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Beyond Air, Inc. |
| Country |
United States |
| Employees |
23 |
| CEO |
Steven A. Lisi |
Stock Information
| Ticker Symbol |
XAIR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: XAIR |
Description
Beyond Air, a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.